Analyst Ratings For ChemoCentryx Inc (NASDAQ:CCXI)
Today, Piper Jaffray Companies initiated coverage on ChemoCentryx Inc (NASDAQ:CCXI) with a Overweight.
There are 3 Hold Ratings, 3 Buy Ratings, 1 Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on ChemoCentryx Inc (NASDAQ:CCXI) is Buy with a consensus target price of $17.10 per share, a potential 50.79% upside.
Some recent analyst ratings include
- 2/11/2019-ChemoCentryx Inc (NASDAQ:CCXI) has coverage initiated with a Overweight rating
- 1/8/2019-ChemoCentryx Inc (NASDAQ:CCXI) has coverage initiated with a Neutral rating and $12.50 price target
- 8/14/2018-ChemoCentryx Inc (NASDAQ:CCXI) gets downgraded to Neutral by JPMorgan Chase & Co. with a price target of $15.00
- 8/13/2018-ChemoCentryx Inc (NASDAQ:CCXI) had its Buy rating reiterated by HC Wainwright with a $20.00 price target
- 6/28/2018-ChemoCentryx Inc (NASDAQ:CCXI) has coverage initiated with a Strong-Buy rating and $18.00 price target
- 5/10/2018-ChemoCentryx Inc (NASDAQ:CCXI) had its Hold rating reiterated by Cowen
- On 1/22/2019 Susan M Kanaya, CFO, sold 37,893 with an average share price of $12.08 per share and the total transaction amounting to $457,747.44.
- On 1/9/2019 Markus J Cappel, Treasurer, sold 8,134 with an average share price of $12.00 per share and the total transaction amounting to $97,608.00.
- On 1/9/2019 Thomas J Schall, Insider, sold 20,170 with an average share price of $12.02 per share and the total transaction amounting to $242,443.40.
- On 1/7/2019 Markus J Cappel, Treasurer, sold 5,069 with an average share price of $12.07 per share and the total transaction amounting to $61,182.83.
- On 1/7/2019 Thomas J Schall, CEO, sold 7,275 with an average share price of $12.04 per share and the total transaction amounting to $87,591.00.
- On 11/7/2018 Thomas J Schall, Insider, sold 7,211 with an average share price of $12.00 per share and the total transaction amounting to $86,532.00.
- On 10/26/2018 Markus J Cappel, Insider, sold 30,237 with an average share price of $11.01 per share and the total transaction amounting to $332,909.37.
About ChemoCentryx Inc (NASDAQ:CCXI)
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
Recent Trading Activity for ChemoCentryx Inc (NASDAQ:CCXI)
Shares of ChemoCentryx Inc closed the previous trading session at 11.34 up +0.28 2.53% with 11 shares trading hands.